We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Community Health Stock for Now
Read MoreHide Full Article
Key Takeaways
CYH is seeing improving occupancy and expanding high-demand services across its hospital network.
CYH is using acquisitions, partnerships and AI tools while divesting non-core assets to streamline operations.
Community Health expects a higher 2025 operating cash flow, though heavy debt and weaker returns persist.
Community Health Systems, Inc. (CYH - Free Report) is well-poised for growth, driven by growing occupancy, acquisitions, partnerships and business streamlining efforts. Over the past year, shares of CYH have grown 6.3%, underperforming the industry’s 25.3% rise.
Community Health — with a market capitalization of $442 million — provides a wide range of inpatient and outpatient medical and surgical services, which include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, rehabilitation services and many more.
Courtesy of solid prospects, this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
Where Do Estimates for CYH Stand?
The Zacks Consensus Estimate for CYH’s 2025 earnings is pegged at 87 cents per share, indicating a 184.5% year-over-year rise. In the past 60 days, it has witnessed one upward estimate revision against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $12.5 billion for 2025. The company beat earnings estimates in two of the past four quarters and missed twice. CYH carries a Value Score of A.
Community Health Systems, Inc. Price, Consensus and EPS Surprise
Community Health continues to focus on investing in high-return markets and physician alignment to drive volume and acuity recovery. It is focusing on expanding high-demand services like neurosurgery, spine care, urology and robotic surgery programs. Occupancy rates have steadily improved, reaching 52.5% in 2024 and averaging 52.8% in the first nine months of 2025. We expect this to climb to 54.4% by year-end.
The company is strategically expanding its reach through targeted acquisitions and partnerships to enhance its offerings, tap into new markets and launch innovative services. It acquired a vascular surgery practice and relocated a large OB/GYN practice onto its Birmingham campus. To streamline operations, CYH has been actively divesting non-core assets, including Lake Norman and ShorePoint in early 2025, and Cedar Park in mid-year. It partnered with Denim Health to integrate conversational AI technology into its Patient Access Center, which handles calls for almost a thousand CYH-affiliated primary care providers.
CYH plans to redirect capital toward lower-cost, higher-return access points such as ambulatory surgery centers, freestanding EDs and urgent care facilities. Alongside this, the company continues to add employed physicians and advanced practice providers, positioning its hospitals for enhanced capacity utilization and a better mix of higher-acuity cases.
CYH’s cash flow situation is expected to strengthen this year. Net operating cash flow is forecasted to be within $600-$700 million for 2025, up from $480 million last year, reflecting growing strength in operations.
Key Concerns
There are a few factors that investors should keep an eye on.
Balance sheet weakness can affect Community Health's financial flexibility. It exited the third quarter with cash and cash equivalents of $123 million, while long-term debt amounted to $10.6 billion. Profitability also lags, with return on invested capital at 8.5% versus the industry’s 9%.
On valuation, CYH trades at a forward 12-month price-to-sales ratio of just 0.04X, far below the industry average of 0.67X.
The Zacks Consensus Estimate for Collegium Pharmaceutical’s current-year earnings of $7.55 per share has witnessed three upward revisions in the past 60 days against no movement in the opposite direction. Collegium Pharmaceutical beat earnings estimates in each of the trailing four quarters, with the average surprise being 10.6%. The consensus estimate for current-year revenues is pegged at $783.9 million, suggesting 24.2% year-over-year growth.
The Zacks Consensus Estimate for ANI Pharmaceuticals’ current-year earnings of $7.56 per share has witnessed five upward revisions in the past 60 days, against no movement in the opposite direction. ANI Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 21.2%. The consensus estimate for current-year revenues is pegged at $870.2 million, suggesting 41.6% year-over-year growth.
The Zacks Consensus Estimate for CorMedix’s current-year earnings of $2.87 per share has witnessed three upward revisions in the past 60 days, against no movement in the opposite direction. CorMedix beat earnings estimates in each of the trailing four quarters, with an average surprise of 27%. The consensus estimate for current-year revenues is pegged at $309.8 million, suggesting 612.7% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain Community Health Stock for Now
Key Takeaways
Community Health Systems, Inc. (CYH - Free Report) is well-poised for growth, driven by growing occupancy, acquisitions, partnerships and business streamlining efforts. Over the past year, shares of CYH have grown 6.3%, underperforming the industry’s 25.3% rise.
Community Health — with a market capitalization of $442 million — provides a wide range of inpatient and outpatient medical and surgical services, which include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, rehabilitation services and many more.
Courtesy of solid prospects, this Zacks Rank #3 (Hold) stock is worth retaining at the moment.
Where Do Estimates for CYH Stand?
The Zacks Consensus Estimate for CYH’s 2025 earnings is pegged at 87 cents per share, indicating a 184.5% year-over-year rise. In the past 60 days, it has witnessed one upward estimate revision against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $12.5 billion for 2025. The company beat earnings estimates in two of the past four quarters and missed twice. CYH carries a Value Score of A.
Community Health Systems, Inc. Price, Consensus and EPS Surprise
Community Health Systems, Inc. price-consensus-eps-surprise-chart | Community Health Systems, Inc. Quote
CYH’s Growth Drivers
Community Health continues to focus on investing in high-return markets and physician alignment to drive volume and acuity recovery. It is focusing on expanding high-demand services like neurosurgery, spine care, urology and robotic surgery programs. Occupancy rates have steadily improved, reaching 52.5% in 2024 and averaging 52.8% in the first nine months of 2025. We expect this to climb to 54.4% by year-end.
The company is strategically expanding its reach through targeted acquisitions and partnerships to enhance its offerings, tap into new markets and launch innovative services. It acquired a vascular surgery practice and relocated a large OB/GYN practice onto its Birmingham campus. To streamline operations, CYH has been actively divesting non-core assets, including Lake Norman and ShorePoint in early 2025, and Cedar Park in mid-year. It partnered with Denim Health to integrate conversational AI technology into its Patient Access Center, which handles calls for almost a thousand CYH-affiliated primary care providers.
CYH plans to redirect capital toward lower-cost, higher-return access points such as ambulatory surgery centers, freestanding EDs and urgent care facilities. Alongside this, the company continues to add employed physicians and advanced practice providers, positioning its hospitals for enhanced capacity utilization and a better mix of higher-acuity cases.
CYH’s cash flow situation is expected to strengthen this year. Net operating cash flow is forecasted to be within $600-$700 million for 2025, up from $480 million last year, reflecting growing strength in operations.
Key Concerns
There are a few factors that investors should keep an eye on.
Balance sheet weakness can affect Community Health's financial flexibility. It exited the third quarter with cash and cash equivalents of $123 million, while long-term debt amounted to $10.6 billion. Profitability also lags, with return on invested capital at 8.5% versus the industry’s 9%.
On valuation, CYH trades at a forward 12-month price-to-sales ratio of just 0.04X, far below the industry average of 0.67X.
Stocks to Consider
Some better-ranked stocks in the Medical space are Collegium Pharmaceutical, Inc. (COLL - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and CorMedix Inc. (CRMD - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Collegium Pharmaceutical’s current-year earnings of $7.55 per share has witnessed three upward revisions in the past 60 days against no movement in the opposite direction. Collegium Pharmaceutical beat earnings estimates in each of the trailing four quarters, with the average surprise being 10.6%. The consensus estimate for current-year revenues is pegged at $783.9 million, suggesting 24.2% year-over-year growth.
The Zacks Consensus Estimate for ANI Pharmaceuticals’ current-year earnings of $7.56 per share has witnessed five upward revisions in the past 60 days, against no movement in the opposite direction. ANI Pharmaceuticals beat earnings estimates in each of the trailing four quarters, with the average surprise being 21.2%. The consensus estimate for current-year revenues is pegged at $870.2 million, suggesting 41.6% year-over-year growth.
The Zacks Consensus Estimate for CorMedix’s current-year earnings of $2.87 per share has witnessed three upward revisions in the past 60 days, against no movement in the opposite direction. CorMedix beat earnings estimates in each of the trailing four quarters, with an average surprise of 27%. The consensus estimate for current-year revenues is pegged at $309.8 million, suggesting 612.7% year-over-year growth.